Jianhua Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianhua Xu has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Xiangyun Teng
Maoming Engineering and Technology Research Center for Southern Medicinal Materials Transformation, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, PR China; Department of Clinical Laboratory, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, PR China
8 shared publicationsYizhe Li
Department of Laboratory Science, West China TianFu Hospital, Sichuan University, Sichuan, China
7 shared publicationsDongdong Liu
Department of Laboratory Science The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
6 shared publicationsJinyong He
Department of Laboratory Medicine Shunde Hospital of Guangzhou University of Chinese Medicine Foshan China
6 shared publicationsAnran Gao
Department of Translational Medicine Research Center and Pharmacy, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, PR China
5 shared publicationsChengshi Fu
Maoming Engineering and Technology Research Center for Southern Medicinal Materials Transformation, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, PR China; Department of Clinical Laboratory, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, PR China
5 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1855696
AdaBoost-based differential diagnosis of gouty arthritis and rheumatoid arthritis: model construction, temporal validation, and SHAP visualization
Background: The phenotypic overlap between gouty arthritis (GA) and Rheumatoid Arthritis (RA) poses diagnostic challenges, particularly in resource-limited settings. This study aims to develop a robust, non-invasive machine learning (ML) framework based on routine hematological parameters to facilitate precise differential diagnosis and to evaluate its robustness in a temporally independent cohort. Methods: Adopting a temporal validation design, we retrospectively analyzed clinical data from a tertiary hospital. A development cohort (2021–2025; n = 9,903) was utilized for model construction, while an independent historical cohort (2015–2020; n = 1,983) served as an time-based internal validation set. Feature selection was performed via LASSO regression, followed by benchmarking nine ML algorithms, including AdaBoost. Performance was evaluated using the Area Under the Curve (AUC) and Decision Curve Analysis (DCA), with interpretability enhanced by the SHAP framework. Results: Six pivotal features were identified, comprising demographics, traditional markers, and novel composite ratios (CHOL/TG). AdaBoost demonstrated superior performance, achieving an AUC of 0.898 in the internal test set and an impressive 0.897 in the time-based internal validation, indicating exceptional generalization. SHAP analysis revealed that beyond conventional markers, CHOL/TG is a key predictor, revealing a unique interaction pattern of lipid metabolism that distinguishes gouty arthritis (GA) from rheumatoid arthritis (RA). Conclusion: We successfully developed and validated an AdaBoost-based model leveraging routine blood indices for precise GA/RA differentiation. Validated across temporal cohorts, this cost-effective tool holds significant promise for optimizing early triage in primary care, while offering novel pathophysiological insights through the lens of lipid metabolism.
- 10 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1855696
Open AccessAdaBoost-based differential diagnosis of gouty arthritis and rheumatoid arthritis: model construction, temporal validation, and SHAP visualization
Background: The phenotypic overlap between gouty arthritis (GA) and Rheumatoid Arthritis (RA) poses diagnostic challenges, particularly in resource-limited settings. This study aims to develop a robust, non-invasive machine learning (ML) framework based on routine hematological parameters to facilitate precise differential diagnosis and to evaluate its robustness in a temporally independent cohort. Methods: Adopting a temporal validation design, we retrospectively analyzed clinical data from a tertiary hospital. A development cohort (2021–2025; n = 9,903) was utilized for model construction, while an independent historical cohort (2015–2020; n = 1,983) served as an time-based internal validation set. Feature selection was performed via LASSO regression, followed by benchmarking nine ML algorithms, including AdaBoost. Performance was evaluated using the Area Under the Curve (AUC) and Decision Curve Analysis (DCA), with interpretability enhanced by the SHAP framework. Results: Six pivotal features were identified, comprising demographics, traditional markers, and novel composite ratios (CHOL/TG). AdaBoost demonstrated superior performance, achieving an AUC of 0.898 in the internal test set and an impressive 0.897 in the time-based internal validation, indicating exceptional generalization. SHAP analysis revealed that beyond conventional markers, CHOL/TG is a key predictor, revealing a unique interaction pattern of lipid metabolism that distinguishes gouty arthritis (GA) from rheumatoid arthritis (RA). Conclusion: We successfully developed and validated an AdaBoost-based model leveraging routine blood indices for precise GA/RA differentiation. Validated across temporal cohorts, this cost-effective tool holds significant promise for optimizing early triage in primary care, while offering novel pathophysiological insights through the lens of lipid metabolism.
- Open Access
- 28 January 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (2)
Exocarpium Citri Grandis ‐Derived Extracellular Vesicle‐Like Particles for Accelerating Wound Healing via Regulating the Protein Expression on the VEGF / AKT Signaling Pathway
Exocarpium Citri Grandis (ECG) is a plant endemic to Huazhou City, Guangdong Province, China. It is utilized both as a health food and in traditional medicine. Recently, Exocarpium Citri Grandis ‐derived extracellular vesicle‐like particles (ECG‐EVLP) have been isolated from ECG. Given the significant advantages of plant‐derived extracellular vesicle‐like particles (P‐EVLP), these particles from various sources have been investigated for their potential in wound healing applications, reducing wound area in vitro or in vivo models. Although the anti‐inflammatory and antioxidant activities of ECG‐EVLP have been established in previous studies, their role in skin wound healing remains unexplored. Our findings indicate that ECG‐EVLP can effectively promote wound healing. In vivo, wound healing was significantly improved in the ECG‐EVLP group compared with the PBS group on Days 3, 7, 11, and 14. In vitro, ECG‐EVLP significantly enhanced L929 cell proliferation at all concentrations (150, 300, and 450 μg/mL) after both 24 and 48 h. For HaCat cells, proliferation increased at the two high concentrations (300 and 450 μg/mL) after 24 h and extended to all concentrations, including all concentrations (150, 300, and 450 μg/mL), after 48 h. The activation of the VEGF/AKT signaling pathway, together with the inhibition of the mitochondrial apoptosis pathway, is likely the underlying mechanism. This interplay promotes cell proliferation, migration, and collagen production, thereby accelerating wound healing following ECG‐EVLP stimulation. Additionally, sphingosine and naringin might be the effective components of ECG‐EVLP in promoting wound healing.
- 28 January 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (2)
Open AccessExocarpium Citri Grandis ‐Derived Extracellular Vesicle‐Like Particles for Accelerating Wound Healing via Regulating the Protein Expression on the VEGF / AKT Signaling Pathway
Exocarpium Citri Grandis (ECG) is a plant endemic to Huazhou City, Guangdong Province, China. It is utilized both as a health food and in traditional medicine. Recently, Exocarpium Citri Grandis ‐derived extracellular vesicle‐like particles (ECG‐EVLP) have been isolated from ECG. Given the significant advantages of plant‐derived extracellular vesicle‐like particles (P‐EVLP), these particles from various sources have been investigated for their potential in wound healing applications, reducing wound area in vitro or in vivo models. Although the anti‐inflammatory and antioxidant activities of ECG‐EVLP have been established in previous studies, their role in skin wound healing remains unexplored. Our findings indicate that ECG‐EVLP can effectively promote wound healing. In vivo, wound healing was significantly improved in the ECG‐EVLP group compared with the PBS group on Days 3, 7, 11, and 14. In vitro, ECG‐EVLP significantly enhanced L929 cell proliferation at all concentrations (150, 300, and 450 μg/mL) after both 24 and 48 h. For HaCat cells, proliferation increased at the two high concentrations (300 and 450 μg/mL) after 24 h and extended to all concentrations, including all concentrations (150, 300, and 450 μg/mL), after 48 h. The activation of the VEGF/AKT signaling pathway, together with the inhibition of the mitochondrial apoptosis pathway, is likely the underlying mechanism. This interplay promotes cell proliferation, migration, and collagen production, thereby accelerating wound healing following ECG‐EVLP stimulation. Additionally, sphingosine and naringin might be the effective components of ECG‐EVLP in promoting wound healing.
- 11 August 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (8) , e70033
Bioinformatics‐Based Exploration of LMO4‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer
The development of acquired drug resistance in breast cancer (BC) significantly compromises treatment efficacy and patient survival, yet the underlying molecular mechanisms remain completely understood. In this study, we investigated the role of the Hippo signaling pathway and its regulatory factor, LIM Domain Only 4 (LMO4), in the acquired Adriamycin (ADR)‐resistant MCF‐7 (AdrR) cells. Using a combination of bioinformatics and experimental approaches, we demonstrated that AdrR cells exhibit defective apoptosis upon ADR treatment, characterized by abnormal expression of apoptotic proteins such as BAX and BCL2. RNA sequencing (RNA‐seq) and ATAC sequencing (ATAC‐seq) revealed significant dysregulation of the Hippo pathway in AdrR cells compared to parental MCF‐7 cells, suggesting its involvement in mediating drug resistance. Further experiments showed that small interfering RNA (siRNA)‐mediated knockdown of LMO4 (siLMO4) altered the expression of apoptotic proteins and partially restored ADR sensitivity in AdrR cells. Mechanistically, LMO4 was found to modulate the Hippo pathway, as evidenced by changes in the nuclear translocation of YAP and the phosphorylation levels of key Hippo pathway components (MST1/2 and YAP). Inhibition of the Hippo pathway using a Lats kinase inhibitor further confirmed its role in regulating drug resistance. Our findings highlight the critical involvement of the LMO4‐Hippo signaling axis in ADR resistance and propose LMO4 as a potential therapeutic target for reversing chemoresistance in BC. This study provides novel insights into the molecular mechanisms of drug resistance and offers a foundation for future research aimed at improving treatment strategies for ADR‐resistant breast cancer.
- 11 August 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (8) , e70033
Bioinformatics‐Based Exploration of LMO4‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer
The development of acquired drug resistance in breast cancer (BC) significantly compromises treatment efficacy and patient survival, yet the underlying molecular mechanisms remain completely understood. In this study, we investigated the role of the Hippo signaling pathway and its regulatory factor, LIM Domain Only 4 (LMO4), in the acquired Adriamycin (ADR)‐resistant MCF‐7 (AdrR) cells. Using a combination of bioinformatics and experimental approaches, we demonstrated that AdrR cells exhibit defective apoptosis upon ADR treatment, characterized by abnormal expression of apoptotic proteins such as BAX and BCL2. RNA sequencing (RNA‐seq) and ATAC sequencing (ATAC‐seq) revealed significant dysregulation of the Hippo pathway in AdrR cells compared to parental MCF‐7 cells, suggesting its involvement in mediating drug resistance. Further experiments showed that small interfering RNA (siRNA)‐mediated knockdown of LMO4 (siLMO4) altered the expression of apoptotic proteins and partially restored ADR sensitivity in AdrR cells. Mechanistically, LMO4 was found to modulate the Hippo pathway, as evidenced by changes in the nuclear translocation of YAP and the phosphorylation levels of key Hippo pathway components (MST1/2 and YAP). Inhibition of the Hippo pathway using a Lats kinase inhibitor further confirmed its role in regulating drug resistance. Our findings highlight the critical involvement of the LMO4‐Hippo signaling axis in ADR resistance and propose LMO4 as a potential therapeutic target for reversing chemoresistance in BC. This study provides novel insights into the molecular mechanisms of drug resistance and offers a foundation for future research aimed at improving treatment strategies for ADR‐resistant breast cancer.
- Open Access
- 18 June 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (6) , e70309
Study on the Mechanism of Fisetin Exerting Anti‐Liver Cancer Effects by Regulating Neutrophil Extracellular Traps
Liver cancer (LC) is among the most prevalent malignant tumors in the digestive tract. The high incidence rate, high metastasis and recurrence rate, poor prognosis, and heterogeneity of liver cancer seriously threaten human health. It is very necessary to search for new drugs and new targets against liver cancer. Natural drugs have been proved to have good anti‐tumor effects. Fisetin, a dietary flavonoid often found in fruits and vegetables, has multiple pharmacological functions such as anti‐inflammation, anti‐oxidation, immune regulation, and anti‐tumor. Firstly, we found in vitro that fisetin could inhibit the proliferation, migration, and invasion of liver cancer cells. Bioinformatics analysis speculated that its anti‐liver cancer mechanism might be related to the formation of neutrophil extracellular traps (NETs). Then, neutrophils were extracted from healthy volunteers, and it was found that fisetin might inhibit the formation of NETs through the AKT/ROS axis. Then, liver cancer cells were cultured in the medium containing NETs. We found that fisetin could weaken the proliferation, migration, and invasion of liver cancer cells induced by NETs. Finally, we found that fisetin could inhibit tumor growth in C57BL/6 mice. Fisetin could inhibit the recruitment of neutrophils and the level of NETs in tumor tissues. In conclusion, we found that fisetin could be used as a new NETs inhibitor and further clarified the anti‐liver cancer effect of fisetin.
- 18 June 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (6) , e70309
Open AccessStudy on the Mechanism of Fisetin Exerting Anti‐Liver Cancer Effects by Regulating Neutrophil Extracellular Traps
Liver cancer (LC) is among the most prevalent malignant tumors in the digestive tract. The high incidence rate, high metastasis and recurrence rate, poor prognosis, and heterogeneity of liver cancer seriously threaten human health. It is very necessary to search for new drugs and new targets against liver cancer. Natural drugs have been proved to have good anti‐tumor effects. Fisetin, a dietary flavonoid often found in fruits and vegetables, has multiple pharmacological functions such as anti‐inflammation, anti‐oxidation, immune regulation, and anti‐tumor. Firstly, we found in vitro that fisetin could inhibit the proliferation, migration, and invasion of liver cancer cells. Bioinformatics analysis speculated that its anti‐liver cancer mechanism might be related to the formation of neutrophil extracellular traps (NETs). Then, neutrophils were extracted from healthy volunteers, and it was found that fisetin might inhibit the formation of NETs through the AKT/ROS axis. Then, liver cancer cells were cultured in the medium containing NETs. We found that fisetin could weaken the proliferation, migration, and invasion of liver cancer cells induced by NETs. Finally, we found that fisetin could inhibit tumor growth in C57BL/6 mice. Fisetin could inhibit the recruitment of neutrophils and the level of NETs in tumor tissues. In conclusion, we found that fisetin could be used as a new NETs inhibitor and further clarified the anti‐liver cancer effect of fisetin.
- Open Access
Stimulation of PSTPIP1 to trigger proinflammatory responses in asymptomatic SARS-CoV-2 infections
- 20 September 2023
- Published by Elsevier in Molecular Immunology
- Vol. 163, 39-47
Longitudinal change trend of the TCR repertoire reveals the immune response intensity of the inactivated COVID-19 vaccine
- 20 September 2023
- Published by Elsevier in Molecular Immunology
- Vol. 163, 39-47
Longitudinal change trend of the TCR repertoire reveals the immune response intensity of the inactivated COVID-19 vaccine
- Open Access
- 5 September 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1203625
The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody
Introduction: At present, there is an urgent need for the rapid and accurate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (NAbs) to evaluate the ability of the human body to resist coronavirus disease 2019 (COVID-19) after infection or vaccination. The current gold standard for neutralizing antibody detection is the conventional virus neutralization test (cVNT), which requires live pathogens and biosafety level-3 (BSL-3) laboratories, making it difficult for this method to meet the requirements of large-scale routine detection. Therefore, this study established a time-resolved fluorescence-blocking lateral flow immunochromatographic assay (TRF-BLFIA) that enables accurate, rapid quantification of NAbs in subjects.Methods: This assay utilizes the characteristic that SARS-CoV-2 neutralizing antibody can specifically block the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and angiotensin-converting enzyme 2 (ACE2) to rapidly detect the content of neutralizing antibody in COVID-19-infected patients and vaccine recipients.Results: When 356 samples of vaccine recipients were measured, the coincidence rate between this method and cVNT was 88.76%, which was higher than the coincidence rate of 76.97% between cVNT and a conventional chemiluminescence immunoassay detecting overall binding anti-Spike-IgG. More importantly, this assay does not need to be carried out in BSL-2 or 3 laboratories.Discussion: Therefore, this product can detect NAbs in COVID-19 patients and provide a reference for the prognosis and outcome of patients. Simultaneously, it can also be applied to large-scale detection to better meet the needs of neutralizing antibody detection after vaccination, making it an effective tool to evaluate the immunoprotective effect of COVID-19 vaccines.
- 5 September 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1203625
Open AccessThe instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody
Introduction: At present, there is an urgent need for the rapid and accurate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (NAbs) to evaluate the ability of the human body to resist coronavirus disease 2019 (COVID-19) after infection or vaccination. The current gold standard for neutralizing antibody detection is the conventional virus neutralization test (cVNT), which requires live pathogens and biosafety level-3 (BSL-3) laboratories, making it difficult for this method to meet the requirements of large-scale routine detection. Therefore, this study established a time-resolved fluorescence-blocking lateral flow immunochromatographic assay (TRF-BLFIA) that enables accurate, rapid quantification of NAbs in subjects.Methods: This assay utilizes the characteristic that SARS-CoV-2 neutralizing antibody can specifically block the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and angiotensin-converting enzyme 2 (ACE2) to rapidly detect the content of neutralizing antibody in COVID-19-infected patients and vaccine recipients.Results: When 356 samples of vaccine recipients were measured, the coincidence rate between this method and cVNT was 88.76%, which was higher than the coincidence rate of 76.97% between cVNT and a conventional chemiluminescence immunoassay detecting overall binding anti-Spike-IgG. More importantly, this assay does not need to be carried out in BSL-2 or 3 laboratories.Discussion: Therefore, this product can detect NAbs in COVID-19 patients and provide a reference for the prognosis and outcome of patients. Simultaneously, it can also be applied to large-scale detection to better meet the needs of neutralizing antibody detection after vaccination, making it an effective tool to evaluate the immunoprotective effect of COVID-19 vaccines.
- Open Access
- 22 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1105689
The biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients
Background: The development of distant metastasis (DM) results in poor prognosis of breast cancer (BC) patients, however, it is difficult to predict the risk of distant metastasis.Methods: Differentially expressed genes (DEGs) were screened out using GSE184717 and GSE183947. GSE20685 were randomly assigned to the training and the internal validation cohort. A signature was developed according to the results of univariate and multivariate Cox regression analysis, which was validated by using internal and external (GSE6532) validation cohort. Gene set enrichment analysis (GSEA) was used for functional analysis. Finally, a nomogram was constructed and calibration curves and concordance index (C-index) were compiled to determine predictive and discriminatory capacity. The clinical benefit of this nomogram was revealed by decision curve analysis (DCA). Finally, we explored the relationships between candidate genes and immune cell infiltration, and the possible mechanism.Results: A signature containing CD74 and TSPAN7 was developed according to the results of univariate and multivariate Cox regression analysis, which was validated by using internal and external (GSE6532) validation cohort. Mechanistically, the signature reflect the overall level of immune infiltration in tissues, especially myeloid immune cells. The expression of CD74 and TSPAN7 is heterogeneous, and the overexpression is positively correlated with the infiltration of myeloid immune cells. CD74 is mainly derived from myeloid immune cells and do not affect the proportion of CD8+T cells. Low expression levels of TSPAN7 is mainly caused by methylation modification in BC cells. This signature could act as an independent predictive factor in patients with BC (p = 0.01, HR = 0.63), and it has been validated in internal (p = 0.023, HR = 0.58) and external (p = 0.0065, HR = 0.67) cohort. Finally, we constructed an individualized prediction nomogram based on our signature. The model showed good discrimination in training, internal and external cohort, with a C-index of 0.742, 0.801, 0.695 respectively, and good calibration. DCA demonstrated that the prediction nomogram was clinically useful.Conclusion: A new immune infiltration related signature developed for predicting metastatic risk will improve the treatment and management of BC patients.
- 22 February 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1105689
Open AccessThe biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients
Background: The development of distant metastasis (DM) results in poor prognosis of breast cancer (BC) patients, however, it is difficult to predict the risk of distant metastasis.Methods: Differentially expressed genes (DEGs) were screened out using GSE184717 and GSE183947. GSE20685 were randomly assigned to the training and the internal validation cohort. A signature was developed according to the results of univariate and multivariate Cox regression analysis, which was validated by using internal and external (GSE6532) validation cohort. Gene set enrichment analysis (GSEA) was used for functional analysis. Finally, a nomogram was constructed and calibration curves and concordance index (C-index) were compiled to determine predictive and discriminatory capacity. The clinical benefit of this nomogram was revealed by decision curve analysis (DCA). Finally, we explored the relationships between candidate genes and immune cell infiltration, and the possible mechanism.Results: A signature containing CD74 and TSPAN7 was developed according to the results of univariate and multivariate Cox regression analysis, which was validated by using internal and external (GSE6532) validation cohort. Mechanistically, the signature reflect the overall level of immune infiltration in tissues, especially myeloid immune cells. The expression of CD74 and TSPAN7 is heterogeneous, and the overexpression is positively correlated with the infiltration of myeloid immune cells. CD74 is mainly derived from myeloid immune cells and do not affect the proportion of CD8+T cells. Low expression levels of TSPAN7 is mainly caused by methylation modification in BC cells. This signature could act as an independent predictive factor in patients with BC (p = 0.01, HR = 0.63), and it has been validated in internal (p = 0.023, HR = 0.58) and external (p = 0.0065, HR = 0.67) cohort. Finally, we constructed an individualized prediction nomogram based on our signature. The model showed good discrimination in training, internal and external cohort, with a C-index of 0.742, 0.801, 0.695 respectively, and good calibration. DCA demonstrated that the prediction nomogram was clinically useful.Conclusion: A new immune infiltration related signature developed for predicting metastatic risk will improve the treatment and management of BC patients.
- Open Access
- 28 December 2022
- Published by Springer Nature in Research Square
The biomarkers related to immune infiltration to predict distant metastasis in patients with breast cancer
Background:The development of distant metastasis (DM) results in poor prognosis of breast cancer (BC) patients, however, it is difficult to predict the risk of distant metastasis. Methods: differentially expressed gene (DEGs) were screened out using GSE184717 and GSE183947.GSE20685 were randomly assigned to the training and the internal validation cohort. A signature was developed according to the results of univariate and multivariate Cox regression analysis,which was validated by using internal and external(GSE6532) validation cohort. Gene set enrichment analysis (GSEA) was used for functional analysis.Finally, a nomogram was constructed and calibration curves and concordance index (C-index) were compiled to determine predictive and discriminatory capacity.The clinical benefit of this nomogram was revealed by decision curve analysis (DCA). Finally, we explored the relationships between candidate genes and immune cell infiltration, and the possible mechanism. Results: A signature containing CD74 and TSPAN7 was developed according to the results of univariate and multivariate Cox regression analysis,which was validated by using internal and external(GSE6532) validation cohort. Mechanistically,the signature reflect the overall level of immune infiltration in tissues, especially myeloid immune cells. The expression of CD74 and TSPAN7 is heterogeneous, low expression levels of TSPAN7 is caused by methylation modification in breast cancer cells, which is negatively correlated with CD74 expression level.CD74 is mainly derived from myeloid immune cells and do not affect the proportion of CD8+T cells. This signature could act as an independent predictive factor in patients with BC (P = 0.01, HR = 0.63), and it has been validated in internal (P = 0.023, HR = 0.58) and external (P = 0.0065, HR = 0.67) cohort. Finally, we constructed a individualized prediction nomogram based on our signature. The model showed good discrimination in training, internal and external cohort, with a C-index of 0.742, 0.801, 0.695 respectively, and good calibration. DCA demonstrated that the prediction nomogram was clinically useful. Conclusion: A new immune infiltration related signature developed for predicting metastatic risk will improve the treatment and management of BC patients
- 28 December 2022
- Published by Springer Nature in Research Square
Open AccessThe biomarkers related to immune infiltration to predict distant metastasis in patients with breast cancer
Background:The development of distant metastasis (DM) results in poor prognosis of breast cancer (BC) patients, however, it is difficult to predict the risk of distant metastasis. Methods: differentially expressed gene (DEGs) were screened out using GSE184717 and GSE183947.GSE20685 were randomly assigned to the training and the internal validation cohort. A signature was developed according to the results of univariate and multivariate Cox regression analysis,which was validated by using internal and external(GSE6532) validation cohort. Gene set enrichment analysis (GSEA) was used for functional analysis.Finally, a nomogram was constructed and calibration curves and concordance index (C-index) were compiled to determine predictive and discriminatory capacity.The clinical benefit of this nomogram was revealed by decision curve analysis (DCA). Finally, we explored the relationships between candidate genes and immune cell infiltration, and the possible mechanism. Results: A signature containing CD74 and TSPAN7 was developed according to the results of univariate and multivariate Cox regression analysis,which was validated by using internal and external(GSE6532) validation cohort. Mechanistically,the signature reflect the overall level of immune infiltration in tissues, especially myeloid immune cells. The expression of CD74 and TSPAN7 is heterogeneous, low expression levels of TSPAN7 is caused by methylation modification in breast cancer cells, which is negatively correlated with CD74 expression level.CD74 is mainly derived from myeloid immune cells and do not affect the proportion of CD8+T cells. This signature could act as an independent predictive factor in patients with BC (P = 0.01, HR = 0.63), and it has been validated in internal (P = 0.023, HR = 0.58) and external (P = 0.0065, HR = 0.67) cohort. Finally, we constructed a individualized prediction nomogram based on our signature. The model showed good discrimination in training, internal and external cohort, with a C-index of 0.742, 0.801, 0.695 respectively, and good calibration. DCA demonstrated that the prediction nomogram was clinically useful. Conclusion: A new immune infiltration related signature developed for predicting metastatic risk will improve the treatment and management of BC patients